Jubilant Ingrevia Ltd Q1 FY27 Earnings Analysis

- The company expects to accelerate growth starting FY27, with sequential revenue and EBITDA growth beginning Q1 FY27 onward. - Specialty Chemicals and Nutrition segments are projected to lead growth, supported by volume recovery and price stability. - CDMO business is poised for nonlinear growth, targeting 3x to 4x scaling over the Pinnacle Journey, driven by multiple innovative molecules in agro, pharma, and personal care. - The large agro contract and other multi-year contracts provide visibility for steady or improved volumes, though some customer volume finalizations remain pending due to market volatility. - Pipeline of 100+ opportunities with Rs. 3,500 crore potential in CDMO, including phased growth (20-25% peak revenue in Year 1, 50-60% in Year 2, 80%+ in Year 3). - Nutrition business, notably Human Nutrition premixes, expected to grow rapidly post recent acquisition. - European market share gains anticipated due to competitor force majeure and plant disruptions. - Sustained Specialty Chemicals EBITDA margins targeted at 23-25%.

- Jubilant Ingrevia aims for at least 20% year-on-year growth in EBITDA for the full year FY27. - Sequential growth in revenue and EBITDA is expected starting from Q1 FY27. - Growth drivers include Specialty Chemicals, Nutrition, and recovery in acetyls segments. - The large $300 million agro CDMO contract, started in March FY27, is a key pillar for growth projections. - The company anticipates a ramp-up in CDMO opportunities across agro, pharma, semiconductors, and personal care, contributing to incremental revenue over 3 years. - Sustainable EBITDA margin guidance for Specialty Chemicals is maintained at 23%-25%, adjusted for corporate overhead. - Management confident of meeting Pinnacle Journey's target of 3x revenue and 4x EBITDA growth by FY30. - Opportunities from acquisitions (e.g., Remidex Pharma) and new geographies (Japan, Southeast Asia) support growth. - Pricing volatility and market disruptions are being managed, with potential positive impacts from European capacity constraints.

- For FY27, Jubilant Ingrevia plans capex in the range of INR 400 crore to INR 500 crore to support growth. - The significant portion of capex will be directed towards the Gajraula Multi-purpose Plant (MPP), expected to commence production in Q4 FY27. - The company has recently capitalized its CDMO plant in March, leading to a reduction in capital work-in-progress. - Continued investments align with the Pinnacle growth journey and are aimed at fueling expansion in Fine Chemicals, CDMO, Nutrition, and Specialty segments. - Strategic acquisition includes Remidex Pharma to strengthen the Human Nutrition premixes portfolio, aiding forward integration. - The capex investment supports scaling up operations, new molecule launches, and capacity enhancements to meet growing demand across pharma, agro, personal care, and semiconductor sectors.

- No explicit mention of any current or future fundraising through debt or equity in the transcript provided. - The company continues to invest through capex in the range of Rs. 400-500 crore yearly for growth (Page 10). - Capital work-in-progress has reduced due to plant capitalization, indicating ongoing internal funding of projects (Page 10). - The management highlights confidence in organic growth and profitability without mentioning the need for external fundraising (Page 15). - Net debt-to-EBITDA ratio stands at 0.99, indicating manageable leverage (Page 6). - Overall, the company seems focused on internal cash flows, operational efficiencies, and organic growth rather than seeking new debt or equity at this time.

- Jubilant Ingrevia currently has over 100 CDMO opportunities with a potential of approximately Rs. 3,500 crore. - There are 20+ confirmed molecules and an additional pipeline of 10+ advanced stage molecules with a peak potential of Rs. 1,100 crore. - The company secured a significant $300 million CDMO contract started shipping in March FY26, which forms a major pillar for growth in the current year. - The overall CDMO order book is around Rs. 1,500 crore with various projects at different stages of development. - New molecules are added every quarter; recent additions include 8 new molecules on top of 15 announced previously. - Growth expectation: New projects typically begin contributing 20-25% of peak revenue in year 1, 50-60% in year 2, and 80%+ in year 3. - Discussions and progress continue with global agrochemical and pharma majors, expanding the CDMO portfolio.